Biotech Values survey #154 (from 12/25/13) can now be laid to rest. The question was which biotech company with a market cap <$1B (on that date) would be the first to be acquired in 2014. The answer choices were: ACHN, AMRN, ARRY, ENTA, EXAS, GERN, MNTA, RNA, SGMO, and SRPT.
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”